CD8A and neoplasm: The results revealed that the low-risk group had high levels of multiple antitumor immune components, including CD8+ T cells, Th1 cells, and Th2 cells, and scored higher on anti-tumor-related pathways, such as HLA (46) and T cell co-stimulation.